Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of July 16, 2026, IMRX trades at $4.81 with a market cap of $333.84M and a P/E ratio of -3.84. IMRX moved -7.56% today. Year to date, IMRX is -27.36%; over the trailing twelve months it is +20.71%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $14.40. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for IMRX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $4.81 |
| Market Cap | $333.84M |
| P/E Ratio | -3.84 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.08 |
| 52-Week Low | $1.10 |
| Volume | 1.22M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-56.02M |
| Gross Margin | 0.00% |
5 analysts cover IMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.40.